SequelSEC

X4 Pharmaceuticals, Inc XFOR

Biological Products, (No Diagnostic Substances) · CIK 0001501697 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$8.67M
Fiscal year ended 2026-06-30
Operating income
-$87.90M
Fiscal year ended 2026-06-30
Free cash flow
Unavailable
Fiscal year ended 2026-06-30

Valuation, from the filing

Public float$14.90MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$0.16Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / revenue2.3×A lower bound on the multiple, because affiliate holdings are excluded.
Float / equity0.1×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Biological Products, (No Diagnostic Substances) filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Revenue YoY growth150.0%87th
Gross margin11.4%15th
Current ratio10.16x83th
R&D / revenue1118.8%68th
Operating margin-1336.7%33th
Net margin-1218.4%36th
SBC / revenue66.1%61th
Long-term debt / equity0.40x58th

X4 Pharmaceuticals, Inc (XFOR) reported revenue of $8.67M and net income of -$90.14M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from X4 Pharmaceuticals, Inc’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).

Income

X4 Pharmaceuticals, Inc income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$8.67M
Cost of revenue$2.93M
Gross profit$5.74M
Operating income-$87.90M
Net income-$90.14M
Research & development$66.39M
Weighted-average diluted sharesUnavailable
Pretax income-$90.17M
Income tax expense-$28.00K
Diluted EPSUnavailable
Selling, general & administrativeUnavailable
General & administrative$34.44M
Selling & marketingUnavailable

Balance

X4 Pharmaceuticals, Inc balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$195.10M
Total assets$253.06M
Current assets$218.86M
Total liabilities$97.61M
Current liabilities$19.37M
Total equity incl. NCI$155.45M
Temporary (mezzanine) equityUnavailable
InventoryUnavailable
Accounts receivable$2.05M
Goodwill$17.35M
Long-term debt$75.00M
Accounts payable$3.93M

Cash flow

X4 Pharmaceuticals, Inc cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow-$83.74M
Capital expendituresUnavailable
Investing cash flow$6.43M
Financing cash flow$233.07M
Net change in cash$155.75M
Stock-based compensation$8.53M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortization$1.67M

Derived

X4 Pharmaceuticals, Inc derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flowUnavailable
Gross margin66.2%
Operating margin-1014.4%
FCF marginUnavailable
SBC / revenue98.4%
Current ratio11.30x
Revenue YoY growth86.0%
Net margin-1040.1%
R&D / revenue766.1%
CapEx / revenueUnavailable
Long-term debt / equity0.48x
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open XFOR in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-06View SEC filing
10-Q · Filed 2026-05-06View SEC filing
10-K · Filed 2026-03-17View SEC filing
10-Q · Filed 2025-11-05View SEC filing
10-Q · Filed 2025-08-08View SEC filing
10-Q · Filed 2025-05-01View SEC filing

Companies in the same industry

ABOS ABPO ACOG ADAPY ADMA ADPT AGEN AGTX AIM ALEC ALGS ALLO

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.